Search

Azimilide

It is not approved for use in any country, but is currently in clinical trials in the United States.

NasoVAX

The compound has already shown to be tolerated with no adverse effects or fever in healthy individuals with a nearly 6-fold cellular immune response in comparison to an injectable vaccine[L16313]. … Created by Altimmune, Inc., NasoVAX is currently being developed for seasonal and pandemic use as it can activate humoral and cellular immune responses.

Isoflurane

A stable, non-explosive inhalation anesthetic, relatively free from significant side effects.

Icotinib

. was given a “May Proceed” from the US FDA to conduct a Phase I study for the evaluation of icotinib as a treatment of EGFR+ Non-Small Cell Lung Cancer (NSCLC). … Icotinib is a potent and specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) Icotinib was approved in China by the SFDA in June, 2011 and in January 2014, Beta Pharma, Inc

ACR-16

ACR-16 is under investigation by NeuroSearch.

Glypromate

In December 2008, the company discontinued further development of the drug after it failed to show an observable effect. … glycine-proline glutamate), a naturally occurring small-molecule neuroprotectant derived from IGF-1 which inhibits caspase III dependent apoptosis, for the potential treatment of neurodegenerative diseases by

Clostridium tetani

Adlinacogene civaparvovec

[L46711] Developed by Sangamo Therapeutics Inc., it is being investigated for the treatment of hemophilia B.[L46706] … It uses proprietary zinc finger nuclease (ZFN) genome editing to insert into the DNA of liver cells a copy of the F9 gene, which controls the production of Factor IX.

ATX-201

It is developed by Kythera Biopharmaceuticals, Inc. for the treatment of actinic keratosis. The company announced the decision to discontinue its ATX-201 clinical program for actinic keratosis.

Col-118

It is a believed to reduce erythema by constricting enlarged blood vessels in facial tissue.